Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.38 |
| ▸ | IKBKB | O14920 | 12/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27119960 | 1.00 | CCNA2 (0.38) | CCNA2CDK2CCNA1IKBKBRAD52 | |
| SCHEMBL27122870 | 0.91 | RAD52 (0.36) | CCNA2CDK2CCNA1IKBKBRAD52 | |
| SCHEMBL30759674 | 0.90 | CCNA2 (0.42) | CCNA2CDK2CCNA1IKBKBRAD52 | |
| SCHEMBL27122153 | 0.90 | RAD52 (0.40) | CCNA2CDK2CCNA1IKBKBRAD52 | |
| SCHEMBL27122184 | 0.90 | IKBKB (0.36) | CCNA2CDK2CCNA1IKBKBRAD52 | |
| SCHEMBL27120495 | 0.90 | CCNA2 (0.42) | CCNA2CDK2CCNA1IKBKBRAD52 | |
| SCHEMBL27119776 | 0.89 | PDE7A (0.36) | CCNA2CDK2CCNA1IKBKBRAD52 | |
| SCHEMBL30759625 | 0.89 | PDE7A (0.36) | CCNA2CDK2CCNA1IKBKBRAD52 | |
| SCHEMBL27122174 | 0.88 | RAD52 (0.36) | CCNA2CDK2CCNA1IKBKBRAD52 | |
| SCHEMBL27120632 | 0.88 | RAD52 (0.39) | CCNA2CDK2CCNA1IKBKBRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | GEDEON RICHTER PLC (HU) | 2026-01-08 | — | — | US | disclosed |
| EP-4577206-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | Celmatix Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | CCNA2 2070/4885CDK2 1537/4885CCNA1 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.